Systemic antiplatelet agents and anticoagulants in eyes with branch retinal vein occlusion
| العنوان: | Systemic antiplatelet agents and anticoagulants in eyes with branch retinal vein occlusion |
|---|---|
| المؤلفون: | Cason B. Robbins, Jane S Kim, Faith A. Birnbaum, Durga S. Borkar, Maria Gomez-Caraballo, Pali P. Singh, Sharon Fekrat, Akshay S. Thomas |
| المصدر: | Therapeutic Advances in Ophthalmology, Vol 13 (2021) Therapeutic Advances in Ophthalmology |
| بيانات النشر: | SAGE Publishing, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | medicine.medical_specialty, Rivaroxaban, optical coherence tomography, genetic structures, medicine.drug_class, business.industry, branch retinal vein occlusion, Anticoagulant, Warfarin, RE1-994, Clopidogrel, medicine.disease, eye diseases, Dabigatran, Ophthalmology, Internal medicine, medicine, Branch retinal vein occlusion, Apixaban, antiplatelet agents, anticoagulation, business, Macular edema, Original Research, medicine.drug |
| الوصف: | Purpose: The purpose of this study was to investigate the effect of systemic antiplatelet agents and anticoagulants on the structural and functional outcomes of eyes with branch retinal vein occlusion (BRVO). Methods: A retrospective longitudinal cohort study was performed on BRVO patients evaluated at a single tertiary care referral center between 2009 and 2017. Medical records were reviewed for antiplatelet agent and anticoagulant use including aspirin, clopidogrel, warfarin, rivaroxaban, apixaban, or dabigatran prior to BRVO onset. In addition, optical coherence tomography (OCT) parameters, clinical outcomes, and treatment patterns were also recorded. Results: A total of 354 BRVO eyes were identified with a mean follow-up time of 36 months. Antiplatelet or anticoagulant use was associated with presence of cystoid macular edema (CME) at presentation after controlling for potential confounding variables in a multivariate logistic regression. Multivariate regression also revealed an association between foveal hemorrhage at presentation and use of antiplatelet or anticoagulant medications. There were no significant differences in visual acuity or prevalence of CME at the final visit in those with antiplatelet/anticoagulant use compared to those not on these agents. Conclusion: Although the use of systemic antiplatelet or anticoagulant agents was associated with increased prevalence of CME and foveal hemorrhage at presentation of BRVO, the use of these medications was not associated with different visual or structural outcomes at the final visit. |
| اللغة: | English |
| تدمد: | 2515-8414 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c11d53ea6b7fdb80eb1ac2199fae7a8d https://doaj.org/article/1be6b740006c4ebf960d5dca7eda98df |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....c11d53ea6b7fdb80eb1ac2199fae7a8d |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 25158414 |
|---|